Lung Cancer Stage III

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Bovine Reinforcement in Stomach, Colorectal and Lung Operation

Induction Chemo-Nivo in Unresectable Stage III NSCLC

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)

Resilience Measurement in Older Adults With Late-Stage Lung Cancer

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)

Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Self-System Therapy for Older Adults With Lung Cancer